A Polymorphism in the Complement Component<i>C1qA</i>Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma

Abstract

Our findings indicate that polymorphisms in the C1qA gene may affect the clinical response and duration of response to rituximab therapy of follicular lymphoma. These results could have direct implications on designing antibodies with improved efficiency and enhance our understanding of the role of complement in monoclonal antibody therapy.